Moxetumomab Pasudotox vs Pembrolizumab
Moxetumomab Pasudotox vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Moxetumomab Pasudotox and Pembrolizumab.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days.
Chemical Properties
Type: Moxetumomab Pasudotox — Antibody drug conjugate; Pembrolizumab — Antibody.